Ashland(US:ASH)2025-05-01 14:23Q2 FY25 Performance - Sales decreased by 17% to $479 million compared to Q2 FY24, but decreased by 5% compared to Q2 FY24 reset[10, 19] - Adjusted EBITDA decreased by 14% to $108 million compared to Q2 FY24, but decreased by 4% to $113 million compared to Q2 FY24 reset[10, 19] - Adjusted EBITDA margin increased by 60 bps to 22.5% compared to Q2 FY24, and increased by 30 bps to 22.2% compared to Q2 FY24 reset[10, 19] - Adjusted EPS decreased by 22% to $0.99 compared to Q2 FY24[10] Business Unit Performance (Sales Change vs Prior Year) - Life Sciences sales decreased by 23% to $172 million, but decreased by 4% to $180 million compared to Q2 FY24 reset[14, 20] - Personal Care sales decreased by 14% to $146 million, but decreased by 5% to $154 million compared to Q2 FY24 reset[14, 27] - Specialty Additives sales decreased by 15% to $134 million, but decreased by 9% to $147 million compared to Q2 FY24 reset[14, 30] - Intermediates sales decreased by 8% to $37 million[23] Strategic Priorities and Outlook - The company is executing initiatives to deliver approximately $90 million in savings through FY27[34, 35] - The company anticipates a $3 to $5 million headwind in 2H from tariffs, and $5 to $7 million annually[44] - FY25 sales outlook is revised to $1.825 - $1.9 billion, and adjusted EBITDA outlook is $400 - $420 million[49]